Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsBristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Sunday 27 September →